Melander A, Wåhlin-Boll E
Acta Endocrinol Suppl (Copenh). 1980;239:9-10.
There is accumulating evidence that salicylate and glipizide may exert a clinically relevant interaction. Therefore, it was of interest to examine the possible interactions of glipizide and antirheumatics of non-salicylate character, e.g., phenyl propionic acid derivatives. The present report deals with the possible interaction between glipizide and indoprofen, a novel and potent antirheumatic agent. The subjects studied were 6 healthy volunteers, who took indoprofen 200 mg t.i.d. for 7 days and a single 5 mg dose of glipizide before and during indoprofen medication. Series of blood samples were obtained for measurements of indoprofen, glipizide, and glucose concentrations in blood. In addition, urine concentrations of indoprofen were determined. The concentrations of glipizide and indoprofen were measured by high-pressure liquid chromatography, and that of glucose ezymatically. The results indicate that chronic indoprofen administration may reduce glipizide concentrations in plasma, but this reduction need not lead to a major influence on the blood glucose response to glipizide.
越来越多的证据表明,水杨酸盐和格列吡嗪可能会产生具有临床意义的相互作用。因此,研究格列吡嗪与非水杨酸盐类抗风湿药(如苯丙酸衍生物)之间可能的相互作用具有重要意义。本报告探讨了格列吡嗪与新型强效抗风湿药吲哚美辛之间可能的相互作用。研究对象为6名健康志愿者,他们连续7天每天服用3次200毫克吲哚美辛,并在服用吲哚美辛之前和期间服用单次5毫克剂量的格列吡嗪。采集一系列血样以测量血液中吲哚美辛、格列吡嗪和葡萄糖的浓度。此外,还测定了尿液中吲哚美辛的浓度。格列吡嗪和吲哚美辛的浓度通过高压液相色谱法测量,葡萄糖浓度通过酶法测量。结果表明,长期服用吲哚美辛可能会降低血浆中格列吡嗪的浓度,但这种降低不一定会对格列吡嗪的血糖反应产生重大影响。